BridgeBio Pharma, Inc. (BBIO) fair value analysis
Nasdaq · Updated 2026-09-06
BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company that develops and seeks to commercialize novel medicines targeting genetic diseases and cancers. The company operates in the United States and internationally, focusing on advancing its pipeline of investigational therapeutics through clinical development.
Valuation status
Awaiting full valuationBBIO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $79.96
- Sector
- Healthcare
- 12-month range
- $53.48–$79.96
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for BBIO
- Shares are trading in the upper third of their 12-month price range of $53.48–$79.96.
- The 14-day relative strength index sits at a neutral 30.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BBIO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the BBIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-06 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BBIO stock undervalued?
BBIO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is BBIO's TickrTrends verdict?
BBIO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is BBIO overbought or oversold?
BBIO's 14-day RSI is in neutral territory - neither overbought nor oversold.